Ann: Anagrelide Project Update, page-42

and this management have the gall to highlight that we have a terminally low EV (refer previous Hopper AGM presentations) - THERE IS A REASON FOR THAT, NOBODY KNOWS WHERE ANYTHING IS AT - YOU WONT TELL US.

- Zolpimist South American MAA (TEVA)
- Zolpimist Asian Territories MAA (Tanabe), has anything been filed in the two years since signing this?
- Zolpimist European territory (per August 2018 investor presentation “expected Q2 FY19”)...no update given since.
- Strides Sumatriptan agreement (signed November 2018, no update given)...that’s ~23 months ago now for those playing along at home.
- Anagrelide update (no timetable, cost out etc) - all vague.
- Cannabinoids...no update since signing agreements with Zelda and Cann.

Its all pretty pathetic really. As an ASX listed company lamenting your own market value, I’d have thought you‘d want shareholders in your corner no?

Perhaps if they were more amenable to this you’d have a re-rated share price and the scorpion juice acquisition could have been closer to reality.